Thu, 06 Feb 2025

Thu, 06 Feb 2025 Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Zepbound and Mounjaro have now underperformed expectations for two straight quarters.

* Eli Lilly reported mixed results for Q4: + Revenue: $13.53 billion (up 45% from same period last year) + Net income: $4.41 billion ($4.88 per share) for Q4
* Sales of Mounjaro: $3.53 billion (up 60% from same period last year, but lower than expected due to "favorable changes" in rebates and discounts)
* Sales of Zepbound: $1.91 billion (below expectations, but became market leader in obesity market with new prescriptions)
* Sales of Jardiance: $1.20 billion (up 50% from same period last year, beating estimates due to one-time benefit)
* Eli Lilly expects "a continuation" of prescription growth for incretin drugs like Zepbound and Mounjaro
* The company also issued fiscal 2025 profit guidance of $22.05 to $23.55 per share, in line with analyst expectations
  >>